Silo Pharma Inc. is a developmental stage biopharmaceutical company founded in 2010 and headquartered in Englewood Cliffs, New Jersey. The company specializes in merging traditional therapeutics with psychedelic research to develop novel treatments for underserved conditions such as PTSD, stress-induced psychiatric disorders, chronic pain conditions, and central nervous system diseases. Silo Pharma focuses on acquiring and licensing technology rights and intellectual property from leading universities and researchers to advance its mission.
Silo Pharma has made significant strides in the biopharmaceutical industry by pioneering the integration of psychedelic medicine into traditional therapeutic frameworks. The company's innovative approach has garnered attention and support from key stakeholders in the medical and scientific communities. By addressing critical gaps in treatment for various psychiatric and CNS disorders, Silo Pharma aims to improve patient outcomes and contribute to the evolving landscape of mental health and pain management therapies.
